‘About 60 per cent of Japan’s population likely to be fully jabbed by Sept-end’

Economy Minister Yasutoshi Nishimura, who is in charge of Covid-19 measures, told NHK public television’s weekly talk show on Sunday that about 60 per cent of the population is expected to be fully vaccinated by the end of September, on par with current levels in Europe

‘About 60 per cent of Japan’s population likely to be fully jabbed by Sept-end’

Meanwhile, demonstrators hold a banner reading ‘Give the children their laughter back’ during a protest against the governmental COVID-19 pandemic measures in Vienna, on Saturday. Pic/AFP

Japan’s government says more than 50 per cent of the population has been fully vaccinated. Vaccine rollouts in the country began in mid-February, months behind many wealthy countries due to its lengthy clinical testing requirement and approval process. Inoculations for elderly patients, which started in April, were also slowed by supply shortages of imported vaccines, but the pace picked up in late May and has since achieved 1 million doses per day.

The government is studying a roadmap for easing restrictions around November when a large majority of the population is expected to be fully vaccinated. That would allow fully vaccinated people and those who test negative to travel, gather for parties or attend mass events.

The progress of vaccinations has helped reduce serious cases and deaths among older people, but infections from virus variants spread explosively in August among younger generations still largely unvaccinated, severely straining health care systems. Japan last Friday extended the ongoing state of emergency in Tokyo and 18 other areas until September 30. It had been scheduled to end Sunday. The measures focus on requests for eateries to close early and not serve alcohol.

Sinovac launches Phase III trial of children’s vax

Chinese pharmaceutical company Sinovac Biotech on Friday launched the Phase III clinical trial of its COVID-19 vaccine on a group of children and teenagers between six months and 17 years old in South Africa. The study, carried out in collaboration with South African company Numolux Group, has enrolled approximately 2,000 participants in the country, who will receive two doses of Sinovac’s CoronaVac vaccine or a placebo, 28 days apart. The efficacy assessment will be based on relevant indicators, the Xinhua news agency reported.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels